As indicated by a recent analysis by the PwC’s Health Research Institute, health care spending costs are likely to climb by 6.8% in 2015. The anticipated spike is more than twofold the normal rate.
Employers often move to high-deductible plans that may require employees to assume more money related risks. A quarter of specialists are currently in high-deductible plans, a more than 200% expansion in the course of recent years. This pattern is not expected to end soon; 44% of employers overviewed by PwC demonstrated that they were considering offering a high-deductible plan to laborers.
Paralleling that pattern is expanded enthusiasm toward private exchanges. Generally a third of employers demonstrated that they are considering moving to a private marketplace that normally would offer laborers more choices of coverage, including high-deductible plans.
Many serious or life threatening health conditions are now being treated with specific meds that are referred to as specialty drugs. These are commonly made using highly advanced methods and are complex to process. They often need special handling and detailed administration. Within the last decade, the amount of speciality drugs has expanded beyond just life threatening conditions to include treatment for chronic diseases such as rheumatoid arthritis and fibromyalgia.
The PwC report additionally raises concern about the impact of speciality pharmaceuticals on the medical economy. As of 2013, 70% of the medications affirmed by the FDA were these kind of higher end pharacon, for example, those intended to battle tumors or HIV symptoms.
Furthermore, while just 4% of patients take these costly drugs, they represented 25% of drugstore expenses a year ago. The usage of these medications are expected to top $400 billion by 2020.